𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Monitoring molecular response in chronic myeloid leukemia

✍ Scribed by Jorge Cortes; Alfonso Quintás-Cardama; Hagop M. Kantarjian

Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
225 KB
Volume
117
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Molecular monitoring in chronic myeloid
Molecular monitoring in chronic myeloid leukemia : Response to tyrosine kinase inhibitors and prognostic implications
✍ Elias Jabbour; Jorge E. Cortes; Hagop M. Kantarjian 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 118 KB

## Abstract The majority of patients with chronic‐phase (CP) chronic myeloid leukemia (CML) who are treated with Bcr‐Abl tyrosine kinase inhibitors such as imatinib and dasatinib achieve cytogenetic disease remission (ie, Philadelphia chromosome‐positive cells undetectable by cytogenetic evaluation